1. DCB Bench testing performed by Boston Scientific Corporation. Data on file at Boston Scientific. Tip profile data on file for 3.00 mm DCBs. Flexibility comparison data on file for 3.50 mm DCBs excluding Selution, data on file for 3.00 mm DCB.
2. Pre-clinical pharmacokinetic studies, data on file at Boston Scientific for AGENT, SeQuent Please and Selution. Magic Touch data derived from product brochure (TCT 2020).
3. Blagosklonny et al. Paclitaxel induces primary and postmitotic G1 arrest in human arterial smooth muscle cells. Cell Cycle. 2004 Aug;3(8):1050-6. Epub 2004 Aug 24.
4. Shahrori ZMF, et al. Drug-Coated Balloons: Recent Evidence and Upcoming Novelties. J Cardiovasc Dev Dis. 2025 May 20;12(5):194. doi: 10.3390/jcdd12050194. PMID: 40422965; PMCID: PMC12112549. Other coronary PTX DCB drug concentrations; SeQuent Please 3 µg/mm², Prevail 3.5 µg/mm², Pantera Lux 3 µg/mm². Also see respective product IFU's.
5. Market data on file at BSC as of July 2023.
6. Hamm, C, et all, AGENT ISR study, Eurointervention, 2020, 3-year comparative clinical study results on file at Boston Scientific Corporation: Data available upon request.
7. Nakamura, M, et all, Drug-coated balloon for the treatment of small vessel coronary artery disease, Circulation Japan 2022.
8. Yeh RW, Shlofmitz R, Moses J, et al. Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis: The AGENT IDE Randomized Clinical Trial. JAMA. 2024;331(12):1015–1024. doi:10.1001/jama.2024.1361


Please review the full IFU for indications for use and operating instructions.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

Boston Scientific
Advancing science for life™

**www.bostonscientific.eu**



IC-1492906-AB
CE 0344

Boston Scientific
Advancing science for life™

# AGENT™
## Drug-Coated Balloon



# Leave the Right **AGENT** Behind

# Perform complex interventions without compromise



## Effortless Deliverability

Navigate and cross complex lesions with ease

## Efficient Drug Transfer

Deliver the optimal dose when it matters most, with less balloon drug load

## Exceptional Long-Term Outcomes

Drive lower event rates consistently as demonstrated by AGENT clinical trials

# Effortless Deliverability

Navigate and cross complex lesions with ease




### Laser Bonded Tip

Improves crossability and reduces tip catch

### Bi-segment Inner Shaft

Maximizes flexibility without compromising push for reduced resistance in tortuous anatomy

### Z-Glide™

Improves tracking with proprietary lubricious coating

# The AGENT Difference

## Ultra-Low Tip Profile[1]




LOWER IS BETTER

## Uncompromised Flexibility[1]




### Distal End Flexibility

Overcoming the rigidity typically introduced by drugcoating matrices (drug + excipient/carrier) is key to optimal distal end flexibility. AGENT DCB demonstrated best-in-class distal end flexibility, minimizing resistance and enhancing deliverability in tortuous anatomy.

LOWER IS BETTER

† Measure of how much work is required to deliver the distal end of the device through a curved simulated artery – how easily does the distal assembly flex.

# Efficient Drug Transfer

Deliver the optimal dose when it matters most, with less balloon drug load. Due to the efficiency of AGENT™ Drug-Coated Balloon's proprietary TransPax™ Coating Technology, AGENT is able to use the lowest paclitaxel dosage compared to other paclitaxel-coated balloons, while still resulting in the highest concentration of drug in the tissue.

## Drug Tissue Concentration*[2]




EFFICIENT TransPax™ COATING TECHNOLOGY

**Lowest balloon paclitaxel load[4]**

**AGENT DCB:**
2 µg/mm²

**Other paclitaxel DCBs:**
3-3.5 µg/mm²

*Independent studies performed using the same FDA recommended and accepted porcine coronary de novo vessel test method.

# TransPax™ coating optimizes the three phases of drug delivery

AGENT DCB is designed with a novel excipient, sharp-edge structure, and uniform crystalline formulation. As a result, AGENT transfers more drug to the tissue and less of it downstream.

| Design Requirement | Paclitaxel (PTX) Drug Choice | AGENT Coating Design |
|---|---|---|
| 1 Targeted Transfer<br>Balloon to vessel wall | Hydrophobic<br>Paclitaxel is durable under hydration | Optimized Excipient<br>Acetyl tributyl citrate (ATBC) maximizes balloon-to-vessel wall transfer |
| 2 Rapid Absorption<br>Vessel wall to tissue | Lipophilic<br>Paclitaxel has a high affinity for fatty tissue | Sharp-Edge Structure<br>Needle-like coating improves tissue penetration |
| 3 Sustained Retention<br>Prolonged tissue concentration | Chemically Stable<br>Paclitaxel has a long half-life | Crystalline Formulation<br>Crystallized coating maintains therapeutic effect |












# Exceptional Long-Term Outcomes

Drive lower event rates consistently as demonstrated by AGENT clinical trials. **Over 4,400 patients** have been evaluated or are undergoing evaluation with AGENT DCB.[5] This includes studies in ISR, de novo lesions, small vessels, large vessels, bifurcations, complex lesions, and patient-specific cases.

## AGENT ISR Study[6]

AGENT demonstrated comparable event rates at 3-years compared to SeQuent Please




## AGENT Japan SV Study[7]

AGENT demonstrated numerically lower levels of late lumen loss compared to SeQuent Please

**-0.03±0.34**
AGENT
**0.03±0.34**
SeQuent Please




# Proven clinical performance

## AGENT US IDE Study[8]

This prospective, multicenter, 2:1 randomized controlled trial showed statistically lower event rates for AGENT DCB at one year.

**41%**
relative risk reduction for **TLF**

**NNT = 9 Patients***




## At one-year, AGENT DCB also demonstrated statistically lower event rates:

**50%**
risk reduction for **TLR**
(13.0% vs. 24.7%, P=0.0005)

**49%**
risk reduction for **TV-MI**
(5.8% vs. 11.1%, P=0.023)

**0%**
**ZERO def/prob ST**
(0.0% vs. 3.2%, P=0.0004)

*Number Needed to Treat to prevent 1 TLF

# Modern PCI Portfolio

With the most comprehensive Modern PCI portfolio on the market, Boston Scientific has the tools needed to See, Prep, and Treat each lesion.

SEE

**AVVIGO™+**
Multi-Modality Guidance System

**OPTICROSS™ HD**
60 MHz Coronary Imaging Catheter



**COMET™ II**
Pressure Guidewire

PREP

**WOLVERINE™**
Cutting Balloon™ Dilatation Device

**ROTAPRO™**
Rotational Atherectomy System

**GUIDEZILLA™**
Guide Extension Catheter

TREAT

**AGENT™**
Drug-Coated Balloon



**SYNERGY™ XD**
Everolimus-Eluting Platinum Chromium Coronary Stent System



SYNERGY
**MEGATRON™**
Everolimus-Eluting Platinum Chromium Coronary Stent System

# AGENT™

## Drug-Coated Balloon




One platform. Expanded potential.
AGENT DCB's 40 mm balloon is here.

AGENT DCB 40 mm Size NOW AVAILABLE

### Drug-Coated Balloon Length (mm)

| Balloon Length<br>Balloon Diameter | 12mm | 15mm | 20mm | 30mm | 40mm |
|---|---|---|---|---|---|
| 2.00 | H74939222201210 | H74939222201510 | H74939222202010 | H74939222203010 | H74939222204010 |
| 2.25 | H74939222221210 | H74939222221510 | H74939222222010 | H74939222223010 | - |
| 2.50 | H74939222251210 | H74939222251510 | H74939222252010 | H74939222253010 | H74939222254010 |
| 2.75 | H74939222271210 | H74939222271510 | H74939222272010 | H74939222273010 | - |
| 3.00 | H74939222301210 | H74939222301510 | H74939222302010 | H74939222303010 | H74939222304010 |
| 3.50 | H74939222351210 | H74939222351510 | H74939222352010 | H74939222353010 | H74939222354010 |
| 4.00 | H74939222401210 | H74939222401510 | H74939222402010 | H74939222403010 | H74939222404010 |